Atrial Natriuretic Peptide Modifies Arterial Blood Pressure Through Nitric Oxide Pathway in Rats

María de los Angeles Costa, Laura V. González Bosc, Mónica P. Majowicz, Norberto A. Vidal, Ana M. Balaszczzuk, Cristina T. Arranz

Abstract—The aim of the present study was to determine the relationship between the hypotensive effect of the atrial natriuretic peptide (ANP) and the nitric oxide (NO) pathway. N^G^-nitro-L-arginine methyl ester bolus (L-NAME, 1 mg/kg) reverted the decrease in mean arterial pressure induced by ANP administration (5 μg/kg bolus and 0.2 μg·kg^−1·min^−1 infusion), and the injection of L-NAME before peptide administration suppressed the ANP hypotensive response. To confirm these findings, a histochemical reaction was used to determine NADPH-diaphorase activity (a NO synthase marker) in the endothelium and smooth muscle of aorta and arterioles of the small and large intestine. ANP increased aorta and arteriole endothelium staining after both in vivo administration and in vitro tissue incubation. In both cases, L-NAME prevented the ANP effect on NADPH-diaphorase activity. Tissues incubated with 8-bromoguanosine 3',5'-cyclic monophosphate mimicked ANP action. In addition, ANP administration increased urinary excretion of NOx end products. These findings indicate that ANP increases NO synthesis capability and NO production and suggest that the cGMP pathway may be involved. In conclusion, the NO pathway could be an intercellular messenger in the ANP endothelium-dependent vasorelaxation mechanism. (Hypertension. 2000;35:1119-1123.)

Key Words: natriuretic peptides ■ nitric oxide ■ arterial pressure ■ NADPH diaphorase ■ cyclic GMP ■ vasodilation

Atrial natriuretic peptide (ANP) and nitric oxide (NO), a free radical in the form of a highly diffusible gas, are vasoactive substances that induce hypotension through their vasorelaxant effects.1-3 Several factors, such as an increase in intracellular cGMP levels, a decrease in cytosolic Ca^{2+} levels, and the activation of calcium-gated potassium channels, are involved in the cellular vasorelaxation mechanism.4,5 An increase in cGMP results in the activation of cGMP-dependent protein kinases and the phosphorylation of proteins involved in the dephosphorylation of myosin light chains, which is a precondition for smooth muscle relaxation.6 Both ANP and NO induce an increase in intracellular cGMP levels, but they do so through different pathways. The cellular effects of ANP are mainly mediated by the guanylyl cyclase-coupled natriuretic receptors, natriuretic peptide receptor (NPR)-A and NPR-B. These receptors are expressed on the surface of different types of cells, including renal endothelial cells, both arterial and venous smooth muscle and endothelial cells, etc. These receptors present an intracellular protein kinaselike domain (KLD), a domain with an autoinhibitory function that mediates adenine nucleotide effects on the guanylyl cyclase domain. On binding of ANP to the extracellular domain of the receptor, a conformational change would ensue, allowing binding of ATP to the KLD. This, in turn, would lead to a further conformational change, freeing the guanylyl cyclase domain from the inhibitory constraint of the KLD and enabling cGMP production.9

NO is produced by 2 different nitric oxide synthase (NOS) enzyme systems: a constitutive enzyme (cNOS) and an inducible enzyme (iNOS) in vascular smooth muscle and endothelium. iNOS is highly regulated by cytokines and other factors.10,11 NO binds the heme moiety of soluble guanylyl cyclase, which results in an allosteric modulation of the enzyme and leads to an increase in cGMP levels. This increase in cGMP production, similar to the cGMP produced by ANP through particulate guanylyl cyclase, leads to a decrease in intracellular Ca^{2+} levels through a multiple cascade of the events proposed.12 On the basis of the above evidence, the aim of the present study was to evaluate potential interactions between ANP and NO in the vascular smooth muscle cells and endothelial cells.

Methods

Animals
Male Wistar rats (weight 250 to 300 g) from the breeding laboratories at Facultad de Farmacia y Bioquímica (Universidad de Buenos Aires, Argentina) were used in each experimental group. Animals were housed in a temperature- and humidity-controlled environment with an automatic light/dark cycle of 12/12 hours, and they were fed...
a standard rat chow (Nutriomentos Purina) and tap water ad libitum until experiments were performed.

**Experimental Design**

Animals were used in compliance with the guidelines of the “Position of the American Heart Association on Research Animal Use.”

**Effect of ANP on Mean Arterial Pressure and Nitrate+Nitrite Urinary Excretion**

Rats were anesthetized with urethane (1 g/kg body wt, IP), and their jugular vein, carotid artery, and urinary bladder were cannulated with polyethylene catheters for drug administration, mean arterial pressure (MAP) recording, and urine collection, respectively. On completion of surgery, a saline infusion (0.05 mL/min) was started and maintained for 45 minutes in all the protocols to ensure stability of hemodynamics and renal parameters. In addition, different protocols were performed.

**Protocol 1**

Six control and 6 experimental animals were injected with saline (1 mL/kg) or ANP (5 μg/kg, 1 mL/kg) and then infused for 90 minutes with saline (0.0393 mL/min) or ANP (0.2 μg · kg⁻¹ · min⁻¹), respectively. Both control and experimental animals received NOS− nitro-L-arginine methyl ester (L-NAME) 1 mg/kg 30 minutes after the beginning of the infusion. MAP was measured at 0, 30, and 90 minutes.

**Protocol 2**

Twelve rats were injected with L-NAME (1 mg/kg), and after 30 minutes they were injected with saline (0.1 mL/kg) or ANP (5 μg/kg, 1 mL/kg) and infused with saline or ANP (0.2 μg · kg⁻¹ · min⁻¹), respectively, for 60 minutes. MAP was measured at 0, 30, and 90 minutes.

**Protocol 3**

Seven animals were infused 60 minutes with saline (control period) and then received an ANP bolus (5 μg/kg) and an infusion of ANP (0.2 μg · kg⁻¹ · min⁻¹). MAP was monitored during the whole procedure. Urine was collected at 60 (control period), 70, 80, and 90 minutes.

**Nitrate+Nitrite Measurement**

The concentration of NOx-derived end products (nitrite and nitrate) in urine samples was determined according to the procedure described in protocol 4. Segments of small intestine, colon, and aorta were removed under surgical conditions, after which, the rats were disposed. To eliminate any blood and intestinal contamination, the removed tissue was carefully washed with Krebs’s solution (mmol/L): NaCl 115.8, KCl 3.8, CaCl₂ 1.2, MgSO₄ 1.1, KH₂PO₄ 1.2, NaHCO₃ 25.4, EDTA 0.002, and glucose 10, bubbled with 95% O₂, and 5% CO₂, to pH 7.4. Finally, the organs were cut into ~10-mm segments.

**Effect of ANP on NADPH Diaphorase Activity**

**Protocol 4**

Twelve animals were divided into 3 groups: Control, ANP, and L-NAME+ANP. Control and ANP rats were infused with saline or ANP (0.2 μg · kg⁻¹ · min⁻¹), respectively, for 30 minutes, at a rate of 0.0393 mL/min. An L-NAME bolus (1 mg/kg) was administered to the L-NAME+ANP group 30 minutes before ANP infusion. After infusion, 150 mm of jejunum-ileum, 30 mm of distal colon, and 30 mm of aorta were removed under surgical conditions, after which, the rats were disposed. To eliminate any blood and intestinal contents, the removed tissue was carefully washed with Krebs’s solution (mmol/L): NaCl 115.8, KCl 3.8, CaCl₂ 1.2, MgSO₄ 1.1, KH₂PO₄ 1.2, NaHCO₃ 25.4, EDTA 0.002, and glucose 10, bubbled with 95% O₂, and 5% CO₂, to pH 7.4. Finally, the organs were cut into ~10-mm segments.

**Protocol 5**

Sixteen rats were anesthetized with ether, and ~150 mm of jejunum-ileum, 30 mm of distal colon, and 30 mm of aorta were removed under surgical conditions. Samples were obtained and processed as described in protocol 4. Segments of small intestine, colon, and aorta were divided into 4 groups: Control, ANP, L-NAME+ANP, and cGMP.

**Statistical Analysis**

Data are presented as the mean ± SE. Differences between control and experimental data were evaluated using 1-way ANOVA followed by Bonferroni’s test. A P value of <0.05 was considered a significant difference.
Results

Table 1 (protocol 1) shows that ANP administration induced a hypotensive effect that was either reverted or suppressed when NO synthesis was inhibited by the injection of L-NAME. Moreover, L-NAME increased MAP in control and ANP-treated rats (Table 1, protocol 2). On the other hand, ANP induced a significant rise of NOx end product excretion with a simultaneous decrease in MAP (basal $587.0\pm6.3; 10$ minutes $70.7\pm3.5; 30$ minutes $69.2\pm2.1; n=6, P<0.01$ versus basal) (Table 2).

An increase in cell staining indicated enhanced NADPH-d activity in the endothelium of aorta and intestinal arterioles from ANP-treated rats. L-NAME blunted this ANP effect. No changes were observed in smooth muscle staining (Table 3, protocol 4).

When aorta and intestinal arterioles were incubated in vitro with ANP, an increase in endothelium staining was observed. In both tissues, preincubation with L-NAME suppressed the ANP effect. Incubation of the tissues with 8-Br-cGMP enhanced aorta and arteriole endothelium staining (Table 3, protocol 5). Photomicrographs showing these effects are presented in Figure 1.

Discussion

On the basis of studies performed by means of endothelium denudation, several authors have postulated that ANP-induced vasodilation was endothelium independent.\cite{19,20} However, present results indicate that an acute inhibition of NO synthesis reverts the hypotensive effect induced by ANP. On the other hand, injection of L-NAME before peptide administration suppresses the ANP hypotensive response, suggesting that an endothelium-derived relaxing factor (ie, NO is involved in the vasodilator effect of ANP). Moreover, the increase in the urinary excretion of NOx end products and the simultaneous decrease in MAP confirm the hypothesis above mentioned.

Furthermore, research was performed to determine whether ANP modifies NOS activity. By means of histochemical reaction of NADPH-d, which is known to indicate NOS, endothelium and vascular smooth muscle have been identified, microscopically, as being capable of synthesizing NO.\cite{21,22} There is evidence that NOS inhibition by L-arginine analogues also inhibits the NOS-associated catalytic NADPH-d activity.\cite{23,25}

The induction of NADPH-d activity by ANP in the endothelium of conductance and resistance vascular beds, and the fact that L-NAME (a NOS inhibitor) completely suppresses this effect, indicate that ANP enhances NO synthesis capability. Moreover, the same results were obtained in rat enterocytes.\cite{26} On the basis of these studies, ANP-induced NO synthesis would involve the L-arginine–NO pathway.\cite{27}

ANP and NO physiological actions are known to be mainly mediated by cGMP.\cite{8,12,28} Given that 8-Br-cGMP mimicked the effect of ANP on NADPH-d activity both in aorta and in arteriole endothelium, guanylyl cyclase-coupled natriuretic receptors, ie, NPR-A and/or NPR-B, could be involved in this ANP action.

However, NPR-C participation in this ANP action cannot be discarded, because NO release stimulation by ANP through NPR-C receptor has been reported in human proximal renal tubular cells.\cite{29,30} NPR-C or clearance receptors have a short cytoplasmatic tail, whose functions include both a Gi-dependent inhibition of adenylate cyclase and the hydrolysis of phosphoinositides by activation of phospho-

<table>
<thead>
<tr>
<th>Experimental Condition</th>
<th>Basal</th>
<th>ANP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time, minutes</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Mean±SE, nmol/min per 100 g</td>
<td>0.08±0.03</td>
<td>0.40±0.11*</td>
</tr>
</tbody>
</table>

Data were analyzed by repeated-measures ANOVA, after being transformed to logarithms, because variances were significantly different ($P<0.05$ by Bartlett’s test for equal variances). *$P<0.001$ vs basal ($n=7$).

<table>
<thead>
<tr>
<th>Protocol 4</th>
<th>OD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>ANP</td>
</tr>
<tr>
<td>Endothelium</td>
<td></td>
</tr>
<tr>
<td>Aorta</td>
<td>0.083±0.006</td>
</tr>
<tr>
<td>Arterioles</td>
<td>0.219±0.006</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Protocol 5</th>
<th>OD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>ANP</td>
</tr>
<tr>
<td>Endothelium</td>
<td></td>
</tr>
<tr>
<td>Aorta</td>
<td>0.265±0.007</td>
</tr>
<tr>
<td>Arterioles</td>
<td>0.102±0.009</td>
</tr>
</tbody>
</table>

Values represent the mean±SE. Protocol 4: *$P<0.01$ vs control, †$P<0.001$ vs ANP ($n=10$ for each group). Protocol 5: ‡$P<0.01$ vs control, §$P<0.001$ vs ANP ($n=17$ for each group). Data were analyzed by ANOVA, followed by Bonferroni’s test.
lipase C, which leads to an enhancement of intracellular Ca\(^{2+}\) levels able to regulate Ca\(^{2+}\)/calmodulin-dependent NOS.\(^{31-34}\)

Murthy et al demonstrated that ANP and cANP-(4-23), a selective NPR-C ligand, initiated identical signaling cascades in vascular smooth muscle, consisting of Ca\(^{2+}\) influx, activation of eNOS via G\(_i1\) and G\(_i2\) proteins, stimulation of cGMP formation, and muscle relaxation.\(^{35,36}\) In addition, Khurana et al suggested that activation of G-proteins stimulates guanylyl cyclase activity of NPR-A.\(^{37}\) Therefore, G-proteins could provide cross-talks mechanisms between ANP and NO pathways in endothelial cells.

Other studies have shown that both ANP, via cGMP elevation, and 8-Br-cGMP alone, enhance NO synthesis under basal and agonist-stimulated conditions in cultured rat cardiac myocytes and vascular smooth muscle cells.\(^{38-40}\) Certainly, Yamamoto et al and Marumo et al\(^{39}\) showed that activation of cGMP-protein kinase by ANP via cGMP up-regulates cytokine-induced iNOS expression after 24-hour incubation in the cells mentioned above. However, on the basis of the present results, this mechanism should be ruled out, because de novo synthesis of the enzyme is unlikely to occur within this brief experimental period.

On the other hand, it has been further demonstrated that ANP activates cGMP-protein kinases inducing endothelial protein phosphorylation.\(^{6,7,9}\) Moreover, it is generally accepted that protein phosphorylation activates cNOS in shear stress.\(^{41}\) Then, ANP could probably activate cNOS in a way similar to shear stress, but the G-protein-related mechanism cannot be discarded.

The enhancement of NO production mediated by ANP could explain the presence of ANP receptors in endothelial cells in spite of the fact that they are also expressed in the smooth muscle, suggesting that NO could act as an intercellular messenger for ANP. This hypothesis is supported by the fact that no effect of ANP on NADPH-d activity was found in smooth muscle cells.

In summary, the present study provides evidence that ANP induces a hypotensive effect by enhancement of NOS activity in the vascular endothelium and NO production through the l-arginine-NO pathway and that cGMP may be involved in this hypotensive effect. The cGMP-signaling pathway has been postulated as an important regulator of cardiovascular and renal physiology,\(^{42}\) the present findings strengthen this hypothesis by associating ANP with the regulation of blood pressure.

**Acknowledgments**

This study was partially supported by grants FA042 (1995-1997), FA002, and FA004 (1998/2000) from the University of Buenos Aires, Argentina. Protocol 1 and 2 were performed by María de los Ángeles Costa. Protocol 3, 4, and 5 were performed by Laura Verónica González Bosc with the participation of María de los Ángeles Costa and Mónica Patricia Majowicz. María de la Angeles Costa and Laura Verónica Gonzalez Bosc performed the statistical analysis. Scientific and technical supervision were provided by Norberto Armando Vidal, Ana María Balaszczuk, and Cristina Teresa Arranz. All the authors participated in the experimental design and manuscript report.
References

Atrial Natriuretic Peptide Modifies Arterial Blood Pressure Through Nitric Oxide Pathway in Rats

María de los Angeles Costa, Laura V. González Bosc, Mónica P. Majowicz, Norberto A. Vidal, Ana M. Balaszczuk and Cristina T. Arranz

Hypertension. 2000;35:1119-1123
doi: 10.1161/01.HYP.35.5.1119

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/35/5/1119

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/